Shockwave C2 Aero Delivers. Our next-gen Coronary IVL device is engineered based on your feedback — and is ready to help you safely and effectively crack calcium with our proven mechanism of action (MOA).
Introducing Shockwave C2 Aero, the latest Aero-volution in coronary calcium modification. Watch this video to see some of the exciting features of this new design, which offers improved deliverability, a more compact rewrap, and more.
Introducing Shockwave C2 Aero, the latest Aero-volution in coronary calcium modification. Watch this video to see some of the exciting features of this new design, which offers improved deliverability, a more compact rewrap, and more.
Christopher L. Brown, MD, describes his early experience with Shockwave C2 Aero plus a recent case, highlighting improved deliverability, better rewrap, and greater flexibility in treating complex calcified multivessel coronary disease.
Christopher L. Brown, MD, describes his early experience with Shockwave C2 Aero plus a recent case, highlighting improved deliverability, better rewrap, and greater flexibility in treating complex calcified multivessel coronary disease.
Yousif Ahmad, MBBS, PhD, FACC, FSCAI, and Brett Wanamaker, MD, FACC, FSCAI, share their feedback after use of Shockwave C2 Aero, describing the technology, sharing two cases, and explaining how they will incorporate it into their practice.
Yousif Ahmad, MBBS, PhD, FACC, FSCAI, and Brett Wanamaker, MD, FACC, FSCAI, share their feedback after use of Shockwave C2 Aero, describing the technology, sharing two cases, and explaining how they will incorporate it into their practice.
Jorge A. Miranda, MD; M. Laiq Raja, MD, FACC, FSCAI
The Rotarex™ Catheter System can help treat acute and subacute limb ischemia, in-stent restenosis, and mixed-morphology PAD lesions while supporting efficient, IVUS-guided revascularization.
The Rotarex™ Catheter System can help treat acute and subacute limb ischemia, in-stent restenosis, and mixed-morphology PAD lesions while supporting efficient, IVUS-guided revascularization.
Introducing Shockwave C2 Aero, the latest Aero-volution in coronary calcium modification. Watch this video to see some of the exciting features of this new design, which offers improved deliverability, a more compact rewrap, and more.
Introducing Shockwave C2 Aero, the latest Aero-volution in coronary calcium modification. Watch this video to see some of the exciting features of this new design, which offers improved deliverability, a more compact rewrap, and more.
Christopher L. Brown, MD, describes his early experience with Shockwave C2 Aero plus a recent case, highlighting improved deliverability, better rewrap, and greater flexibility in treating complex calcified multivessel coronary disease.
Christopher L. Brown, MD, describes his early experience with Shockwave C2 Aero plus a recent case, highlighting improved deliverability, better rewrap, and greater flexibility in treating complex calcified multivessel coronary disease.
Yousif Ahmad, MBBS, PhD, FACC, FSCAI, and Brett Wanamaker, MD, FACC, FSCAI, share their feedback after use of Shockwave C2 Aero, describing the technology, sharing two cases, and explaining how they will incorporate it into their practice.
Yousif Ahmad, MBBS, PhD, FACC, FSCAI, and Brett Wanamaker, MD, FACC, FSCAI, share their feedback after use of Shockwave C2 Aero, describing the technology, sharing two cases, and explaining how they will incorporate it into their practice.
Brian C. Case, MD; Bailey Ann Richardson, MSN, AGNP, RN-BC, RNFA, CNOR, RCIS
Bailey Richardson, MSN, speaks with Brian Case, MD, about coronary microvascular dysfunction and why “normal” angiography can miss the cause of symptoms in patients with angina with non-obstructive coronary arteries (ANOCA).
Bailey Richardson, MSN, speaks with Brian Case, MD, about coronary microvascular dysfunction and why “normal” angiography can miss the cause of symptoms in patients with angina with non-obstructive coronary arteries (ANOCA).
In this 29-minute video (chapters available), Matthew H. Gonzalez, MD, discusses how pulmonary artery pressure monitoring with the CardioMEMS™ HF System made by Abbott shifts management from reactive to proactive by detecting hemodynamic...
In this 29-minute video (chapters available), Matthew H. Gonzalez, MD, discusses how pulmonary artery pressure monitoring with the CardioMEMS™ HF System made by Abbott shifts management from reactive to proactive by detecting hemodynamic...
Dr. Tanvir Bajwa highlights how the Stedi Extra Support Guidewire from Medtronic is designed to improve tracking, stability, and coaxial deployment during TAVR, and shares early experience suggesting it can support more predictable implant...
Dr. Tanvir Bajwa highlights how the Stedi Extra Support Guidewire from Medtronic is designed to improve tracking, stability, and coaxial deployment during TAVR, and shares early experience suggesting it can support more predictable implant...
Market tends are showing that more procedures are moving to out-of-hospital care settings, such as ambulatory surgery centers (ASCs) and office-based labs (OBLs) due to financial and operational benefits to the healthcare system and desire to...
Market tends are showing that more procedures are moving to out-of-hospital care settings, such as ambulatory surgery centers (ASCs) and office-based labs (OBLs) due to financial and operational benefits to the healthcare system and desire to...
“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy without relying on additional upfront ancillary devices," said Margaret McEntegart, MD, PhD.
“Shockwave C2 Aero makes it easier to navigate tortuous coronary anatomy without relying on additional upfront ancillary devices," said Margaret McEntegart, MD, PhD.
BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
DEEPER CORONARY is a first-in-human pilot study designed to evaluate the short-term safety of the investigational coronary Spur Elute System as a primary treatment for coronary ISR.
DEEPER CORONARY is a first-in-human pilot study designed to evaluate the short-term safety of the investigational coronary Spur Elute System as a primary treatment for coronary ISR.
SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the acquisition of the Pounce™...
SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the acquisition of the Pounce™...
EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools.
EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools.
Financing supports clinical advancement and commercialization of the company’s dual-modality IVL platform, with proceeds funding peripheral commercial launch and coronary program development.
Financing supports clinical advancement and commercialization of the company’s dual-modality IVL platform, with proceeds funding peripheral commercial launch and coronary program development.
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease.
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease.
Newly issued patents in Australia and Japan cover the company's Artero™ E-IVL and Sola™ L-IVL platforms as FastWave advances toward peripheral and coronary IDE trials.
Newly issued patents in Australia and Japan cover the company's Artero™ E-IVL and Sola™ L-IVL platforms as FastWave advances toward peripheral and coronary IDE trials.
The eLym System is an investigational catheter-based device for treating patients with acute decompensated heart failure (ADHF) by supporting lymphatic drainage.
The eLym System is an investigational catheter-based device for treating patients with acute decompensated heart failure (ADHF) by supporting lymphatic drainage.
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026
Orchestra BioMed and Medtronic plc, the Company’s strategic collaborator for the BACKBEAT Trial,...
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026
Orchestra BioMed and Medtronic plc, the Company’s strategic collaborator for the BACKBEAT Trial,...
Orchestra BioMed targeting...
05/13/2026
Cath Lab Digest
About Shockwave
Shockwave IVL pioneers innovative technologies that help improve lives around the globe. The Shockwave IVL system is transforming standards of care and driving better outcomes for underserved patients. Shockwave IVL: In the U.S.: Rx only. Prior to use, please reference the Important Safety Information for more information on indications, contraindications, warnings, precautions and adverse events.